Cresset Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-2,855
| Closed | -$329K | – | 1934 |
|
|
2024
Q3 | $329K | Sell |
2,855
-289
| -9% | -$33.3K | ﹤0.01% | 1725 |
|
|
2024
Q2 | $433K | Buy |
3,144
+145
| +5% | +$20K | ﹤0.01% | 1479 |
|
|
2024
Q1 | $414K | Sell |
2,999
-554
| -16% | -$76.4K | ﹤0.01% | 1414 |
|
|
2023
Q4 | $468K | Buy |
3,553
+101
| +3% | +$13.3K | ﹤0.01% | 1247 |
|
|
2023
Q3 | $388K | Buy |
3,452
+663
| +24% | +$74.6K | ﹤0.01% | 1277 |
|
|
2023
Q2 | $263K | Buy |
+2,789
| New | +$263K | ﹤0.01% | 1451 |
|
|
2021
Q4 | – | Sell |
-2,469
| Closed | -$237K | – | 1235 |
|
|
2021
Q3 | $237K | Buy |
+2,469
| New | +$237K | ﹤0.01% | 954 |
|
|
2019
Q2 | – | Sell |
-922
| Closed | -$81K | – | 1239 |
|
|
2019
Q1 | $81K | Buy |
922
+21
| +2% | +$1.85K | ﹤0.01% | 621 |
|
|
2018
Q4 | $64K | Buy |
+901
| New | +$64K | ﹤0.01% | 422 |
|